Pharmacological Treatment of Obsessive-Compulsive Disorder

Pittenger, Christopher; Bloch, Michael H.

doi:10.1016/j.psc.2014.05.006

Cited by 222Obsessive-Compulsive Spectrum DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychoanalysis and Psychopathology Research

Pharmacological Treatment of Obsessive-Compulsive Disorder

Open access

Pittenger, Christopher, Bloch, Michael H.·2014·Psychiatric Clinics of North America

DOI 10.1016/j.psc.2014.05.006PMC PMC4143776

Open this paper in CoChat — free account

Abstract

Obsessive-compulsive disorder (OCD) affects up to 2.5% of the population of the course of a lifetime and produces substantial morbidity. Approximately 70% of patients can experience significant symptomatic relief with appropriate pharmacotherapy. Selective serotonin reuptake inhibitors are the mainstay of pharmacological treatment. These drugs are typically used at higher doses and for longer periods than in depression. Proven second-line treatments include the tricyclic clomipramine and the addition of low-dose neuroleptic medications. OCD refractory to available treatments remains a profound clinical challenge.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.psc.2014.05.006

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Patients with OCD need higher doses of medication compared to other anxiety disorders.
“Since patients with OCD need higher doses of medication compared to other anxiety disorders, this lack of information may compromise the internal validity of this study [50].”
From Personalized exposure and experience sampling method feedback versus exposure as usual for obsessive–compulsive disorder: a study protocol for a randomized controlled trial (2024) · cites this paper as [50]
The Serotonin reuptake inhibitors section says SSRIs are often used at higher doses for OCD, and the Conclusion says higher doses are often required relative to standard treatment for major depressive disorder. The paper does not establish the claimed comparison with other anxiety disorders, and its dosing discussion concerns SSRIs rather than medication generally. (LLM, conf=0.87)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders(DSM)
Leong, F. T. L. (2008) · Sage eBooks · doi:10.4135/9781412963978.n182 · Cited by 10,858 · see citing works
Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947 · see citing works
Cognitive-Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents With Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study (POTS) Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.292.16.1969 · Cited by 1,107 · see citing works
Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinctionof Fear
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063 · see citing works
Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive–compulsive disorder
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048 · see citing works
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028 · see citing works
Facilitation of Conditioned Fear Extinction by Systemic Administration or Intra-Amygdala Infusions of d-Cycloserine as Assessed with Fear-Potentiated Startle in Rats
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815 · see citing works
Diagnostic and Statistical Manual of Mental Disorders (DSM)
Cooper, R. (2017) · KNOWLEDGE ORGANIZATION · doi:10.5771/0943-7444-2017-8-668 · Cited by 770 · see citing works
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635 · see citing works
Self-citation
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510 · see citing works
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450 · see citing works
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426 · see citing works
Self-citation
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond
Krystal, J. H., Sanacora, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.026 · Cited by 406 · see citing works
Efficacy of Fluvoxamine in Obsessive-Compulsive Disorder
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810010038006 · Cited by 391 · see citing works
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386 · see citing works
Obsessive-Compulsive Disorder
Insel, T. R. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.04390010015002 · Cited by 348 · see citing works
Glutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344 · see citing works
Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)
Soomro, G. M., Altman, D. G., Rajagopal, S., & Oakley Browne, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001765.pub3 · Cited by 342 · see citing works
The pharmacologic profile of mirtazapine.
de Boer, T. (1996) · PubMed · Cited by 330 · see citing works
Meta-analysis of the dose-response relationship of SSRI in obsessive–compulsive disorder
Bloch, M. H., McGuire, J., Landeros-Weisenberger, A., Leckman, J. F., & Pittenger, C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.50 · Cited by 317 · see citing works
Self-citation
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314 · see citing works
Self-citation
Obsessive Compulsive Disorder
Hudak, R., & Gannon, J. M. (2022) · Current clinical practice · doi:10.1007/978-3-030-98709-1_5 · Cited by 306 · see citing works
Cognitive Behavior Therapy Augmentation of Pharmacotherapy in Pediatric Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study II (POTS II) Randomized Controlled Trial
Franklin, M. E., Sapyta, J., Freeman, J. B., Khanna, M., Compton, S., Almirall, D., Moore, P., Choate-Summers, M., Garcia, A., Edson, A. L., et al. (2011) · JAMA · doi:10.1001/jama.2011.1344 · Cited by 278 · see citing works
Effectiveness of antidepressants: Meta-analysis of dose-effect relationships in randomised clinical trials
Bollini, P., Pampaliona, S., Tibaldi, G., Kupelnick, B., & Munizza, C. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.4.297 · Cited by 274 · see citing works
Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder: A Randomized Clinical Trial
Simpson, H. B., Foa, E. B., Liebowitz, M. R., Huppert, J. D., Cahill, S., Maher, M. J., McLean, C. P., Bender, J., Marcus, S. M., Williams, M. T., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1932 · Cited by 248 · see citing works
Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211 · see citing works
Inositol treatment of obsessive-compulsive disorder
Fux, M., Levine, J., Aviv, A., & Belmaker, R. H. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.9.1219 · Cited by 209 · see citing works
Multivariate Meta-Analysis of Controlled Drug Studies for Obsessive-Compulsive Disorder
Ackerman, D. L., & Greenland, S. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00012 · Cited by 202 · see citing works
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder
Lafleur, D. L., Pittenger, C., Kelmendi, B., Gardner, T., Wasylink, S., Malison, R. T., Sanacora, G., Krystal, J. H., & Coric, V. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0246-6 · Cited by 200 · see citing works
Self-citation
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00004 · Cited by 177 · see citing works
Self-citation
Glutamate receptors in extinction and extinction-based therapies for psychiatric illness
Myers, K. M., Carlezon, W., & Davis, M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.88 · Cited by 175 · see citing works
Anti-Brain Autoantibodies and Altered Excitatory Neurotransmitters in Obsessive–Compulsive Disorder
Bhattacharyya, S., Khanna, S., Chakrabarty, K., Mahadevan, A., Christopher, R., & Shankar, S. K. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.77 · Cited by 172 · see citing works
Obsessive-Compulsive Disorder
Leonard, H. L., Ale, C. M., Freeman, J. B., Garcia, A. M., & Ng, J. (2005) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.06.002 · Cited by 172 · see citing works
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch, M. H., Wasylink, S., Landeros-Weisenberger, A., Panza, K. E., Billingslea, E., Leckman, J. F., Krystal, J. H., Bhagwagar, Z., Sanacora, G., & Pittenger, C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.028 · Cited by 162 · see citing works
Self-citation
A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c856de · Cited by 158 · see citing works
Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study
Ghaleiha, A., Entezari, N., Modabbernia, A., Najand, B., Askari, N., Tabrizi, M., Ashrafi, M., Hajiaghaee, R., & Akhondzadeh, S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.015 · Cited by 152 · see citing works
A Double-Blind Switch Study of Paroxetine and Venlafaxine in Obsessive-Compulsive Disorder
Denys, D. A. J. P., van Megen, H. J. G. M., van der Wee, N. J. A., & Westenberg, H. G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0106 · Cited by 144 · see citing works
A Critical Review of Magnetic Resonance Spectroscopy Studies of Obsessive-Compulsive Disorder
Brennan, B. P., Rauch, S. L., Jensen, J. E., & Pope, H. G. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.023 · Cited by 141 · see citing works
N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
Afshar, H., Roohafza, H., Mohammad-Beigi, H., Haghighi, M., Jahangard, L., Shokouh, P., Sadeghi, M., & Hafezian, H. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318272677d · Cited by 136 · see citing works
Double-Blind Treatment With Oral Morphine in Treatment-Resistant Obsessive-Compulsive Disorder
Koran, L. M., Aboujaoude, E. N., Bullock, K. D., Franz, B., Gamel, N. N., & Elliott, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0312 · Cited by 132 · see citing works
Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder
Berlin, H. A., Koran, L. M., Jenike, M. A., Shapira, N. A., Chaplin, W. F., Pallanti, S., & Hollander, E. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05266gre · Cited by 131 · see citing works
In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)
Haghighi, M., Jahangard, L., Mohammad-Beigi, H., Bajoghli, H., Hafezian, H., Rahimi, A., Afshar, H., Holsboer‐Trachsler, E., & Brand, S. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3067-z · Cited by 110 · see citing works
Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study
Bruno, A., Micò, U., Pandolfo, G., Mallamace, D., Abenavoli, E., Di Nardo, F., D’Arrigo, C., Spina, E., Zoccali, R. A., & Muscatello, M. R. A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431751 · Cited by 103 · see citing works
Meta‐analysis of association between obsessive‐compulsive disorder and the 3′ region of neuronal glutamate transporter gene <i>SLC1A1</i>
Stewart, S. E., Mayerfeld, C., Arnold, P. D., Crane, J. R., O'Dushlaine, C., Fagerness, J. A., Yu, D., Scharf, J. M., Chan, E., Kassam, F., et al. (2013) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32137 · Cited by 102 · see citing works
Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder
Dell’Osso, B. M., Nestadt, G., Allen, A., & Hollander, E. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0411 · Cited by 97 · see citing works
Memantine augmentation for refractory obsessive–compulsive disorder
Pasquini, M., & Biondi, M. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.04.013 · Cited by 97 · see citing works
Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive–compulsive disorder: a double-blind cross-over study
Fux, M., Benjamin, J., & Belmaker, R. H. (1999) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145799001546 · Cited by 97 · see citing works
Memantine for Treatment-Resistant OCD
Poyurovsky, M., Weizman, R., Weizman, A., & Koran, L. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.2191-a · Cited by 97 · see citing works
Early Onset of Response With Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder: A Meta-Analysis
Issari, Y., Jakubovski, E., Bartley, C. A., Pittenger, C., & Bloch, M. H. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09758 · Cited by 92 · see citing works
Self-citation
Differential Efficacy of Memantine for Obsessive-Compulsive Disorder vs. Generalized Anxiety Disorder: An Open-Label Trial
Feusner, J. D., Kerwin, L. E., Saxena, S., & Bystritsky, A. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4096 · Cited by 91 · see citing works
Escitalopram prevents relapse of obsessive-compulsive disorder
Fineberg, N. A., Tonnoir, B., Lemming, O. M., & Stein, D. J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.11.005 · Cited by 83 · see citing works
Riluzole Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder
Pittenger, C., Kelmendi, B., Wasylink, S., Bloch, M. H., & Coric, V. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181727548 · Cited by 82 · see citing works
Self-citation
Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults
Greenberg, W. M., Benedict, M. M., Doerfer, J., Perrin, M., Panek, L., Cleveland, W. L., & Javitt, D. C. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.10.007 · Cited by 80 · see citing works
Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial
Mowla, A., Khajeian, A., Sahraian, A., Chohedri, A., & Kashkoli, F. (2010) · CNS Spectrums · doi:10.1017/s1092852912000065 · Cited by 79 · see citing works
Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder
Koran, L. M., Aboujaoude, E., & Gamel, N. N. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04605 · Cited by 79 · see citing works
A double‐blind, placebo‐controlled pilot study of ondansetron for patients with obsessive‐compulsive disorder
Soltani, F., Sayyah, M., Feizy, F., Malayeri, A., Siahpoosh, A., & Motlagh, I. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1145 · Cited by 78 · see citing works
Naloxone administration in obsessive-compulsive disorder: report of two cases
Insel, T. R., & Pickar, D. (1983) · American Journal of Psychiatry · doi:10.1176/ajp.140.9.1219 · Cited by 76 · see citing works
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.
Krystal, J. H., Tolin, D. F., Sanacora, G., Castner, S. A., Williams, G. V., Aikins, D. E., Hoffman, R. E., & D'Souza, D. C. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.002 · Cited by 76 · see citing works
Comparative efficacy of antidepressants in preventing relapse in anxiety disorders — A meta-analysis
Donovan, M. R., Glue, P., Kolluri, S., & Emir, B. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.021 · Cited by 74 · see citing works
Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
Pallanti, S., Quercioli, L., & Koran, L. M. (2002) · PubMed · Cited by 73 · see citing works
Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder
Brandl, E. J., Tiwari, A. K., Zhou, X., Deluce, J. E., Kennedy, J. L., Müller, D., & Richter, M. A. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.12 · Cited by 70 · see citing works
Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
Szegedi, A., Wetzel, H., Leal, M., Härtter, S., & Hiemke, C. (1996) · PubMed · Cited by 67 · see citing works
Venlafaxine in Treatment-Resistant Obsessive-Compulsive Disorder
Hollander, E., Friedberg, J. P., Wasserman, S., Allen, A., Birnbaum, M., & Koran, L. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0508 · Cited by 66 · see citing works
Ondansetron Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder
Pallanti, S., Bernardi, S., Antonini, S., Singh, N., & Hollander, E. (2009) · CNS Drugs · doi:10.2165/11530240-000000000-00000 · Cited by 66 · see citing works
Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder
Askari, N., Moin, M., Sanati, M. H., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Najand, B., Salimi, S., Tabrizi, M. H., Ashrafi, M., et al. (2012) · CNS Drugs · doi:10.2165/11635850-000000000-00000 · Cited by 65 · see citing works
Citalopram Treatment of Compulsive Shopping
Pallanti, S., Quercioli, L., & Koran, L. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0908 · Cited by 62 · see citing works
Nutraceuticals in the treatment of Obsessive Compulsive Disorder (OCD): A review of mechanistic and clinical evidence
Camfield, D., Sarris, J. J., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.02.011 · Cited by 61 · see citing works
Complementary medicine, self-help, and lifestyle interventions for Obsessive Compulsive Disorder (OCD) and the OCD spectrum: A systematic review
Sarris, J., Camfield, D., & Berk, M. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.051 · Cited by 59 · cited 1× · see citing works
“There has been significant interest in a variety of over-the-counter (OTC) agents for OCD [61, 62].”
Background
Lamotrigine Augmentation of Serotonin Re-Uptake Inhibitors in Obsessive–Compulsive Disorder
Kumar, T. C. R., & Khanna, S. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2000.0751c.x · Cited by 59 · see citing works
Effectiveness of Long-Term Augmentation with Citalopram to Clomipramine in Treatment-Resistant OCD Patients
Marazziti, D., Golia, F., Consoli, G., Presta, S., Pfanner, C., Carlini, M., Mungai, F., & Dell’Osso, M. C. (2008) · CNS Spectrums · doi:10.1017/s1092852900014024 · Cited by 45 · see citing works
Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: Improvement with treatment and worsening following discontinuation
Pallanti, S., Bernardi, S., Antonini, S., Singh, N., & Hollander, E. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.003 · Cited by 42 · see citing works
Sarcosine Therapy for Obsessive Compulsive Disorder
Wu, P.-L., Tang, H., Lane, H., Tsai, C., & Tsai, G. E. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182189878 · Cited by 40 · see citing works
Pharmacogenetics of Obsessive–Compulsive Disorders
Brandl, E. J., Müller, D. J., & Richter, M. A. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.133 · Cited by 40 · see citing works
Obsessive Compulsive Disorder
Soomro, G. M. (2012) · SpringerReference · doi:10.1007/springerreference_223981 · Cited by 32 · see citing works
Genetics and Personalized Medicine in Antidepressant Treatment
Gvozdic, K., Brandl, E. J., Taylor, D. L., & Müller, D. J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803523617 · Cited by 25 · see citing works
Safety of High-Dosage Citalopram
Zivin, K., Pfeiffer, P. N., Bohnert, A. S. B., Ganoczy, D. A., Blow, F. C., Nallamothu, B. K., & Kales, H. C. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13081052 · Cited by 13 · see citing works
Citalopram, escitalopram, and the QT interval.
(2013) · PubMed · Cited by 1 · see citing works
Convergent and divergent validity of the Beck Anxiety Inventory for patients with panic disorder and agoraphobia
de Beurs, E., Wilson, K. A., Chambless, D. L., Goldstein, A. J., & Feske, U. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)6:4

Flagged first, then by citations

1 of the 79 references couldn’t be matched to a known paper.

Sorted by citations

Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder
Goodman, W. K., Storch, E. A., & Sheth, S. A. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111601 · Cited by 268 · see citing works
Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults
Fineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150 · see citing works
Pharmacological and behavioral treatment for trichotillomania: an updated systematic review with meta-analysis
Farhat, L. C., Olfson, E., Nasir, M., Levine, J. L. S., Li, F., Miguel, E. C., & Bloch, M. H. (2020) · Depression and Anxiety · doi:10.1002/da.23028 · Cited by 133 · see citing works
Self-citation
Variability and anatomical specificity of the orbitofrontothalamic fibers of passage in the ventral capsule/ventral striatum (VC/VS): precision care for patient-specific tractography-guided targeting of deep brain stimulation (DBS) in obsessive compulsive disorder (OCD)
Makris, N., Yogesh Rathi, A., Mouradian, P., Bonmassar, G., Papadimitriou, G., Ing, W. I., Yeterian, E. H., Kubicki, M. R., Eskandar, E. N., Wald, L. L., et al. (2015) · Brain Imaging and Behavior · doi:10.1007/s11682-015-9462-9 · Cited by 128 · see citing works
DISSECTING OCD CIRCUITS: FROM ANIMAL MODELS TO TARGETED TREATMENTS: Review: Dissecting OCD Circuits: Animals to Treatments
Ahmari, S. E., & Dougherty, D. D. (2015) · Depression and Anxiety · doi:10.1002/da.22367 · Cited by 128 · see citing works
Neuroscientifically Informed Formulation and Treatment Planning for Patients With Obsessive-Compulsive Disorder: A Review
Dougherty, D. D., Brennan, B. P., Stewart, S. E., Wilhelm, S., Widge, A. S., & Rauch, S. L. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0930 · Cited by 131 · see citing works
Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression
Thomas, S. J., Shin, M., McInnis, M. G., & Bostwick, J. R. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1576 · Cited by 116 · see citing works
The anterior limb of the internal capsule: Anatomy, function, and dysfunction
Mithani, K., Davison, B., Meng, Y., & Lipsman, N. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112588 · Cited by 66 · see citing works
Social Cognition and Obsessive-Compulsive Disorder: A Review of Subdomains of Social Functioning
Jansen, M., Overgaauw, S., & de Bruijn, E. R. A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00118 · Cited by 64 · see citing works
Glutamatergic agents for OCD and related disorders
Pittenger, C. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0051-8 · Cited by 62 · see citing works
Self-citation
Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
Edinoff, A. N., Swinford, C. R., Odisho, A. S., Burroughs, C. R., Stark, C. W., Raslan, W. A., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.39576 · Cited by 60 · see citing works
Therapies for obsessive-compulsive disorder: Current state of the art and perspectives for approaching treatment-resistant patients
Swierkosz-Lenart, K., Santos, J. F. A. D., Elowe, J., Clair, A.-H., Bally, J. F., Riquier, F., Bloch, J., Draganski, B., Clerc, M.-T., Moyano, B. P., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1065812 · Cited by 67 · see citing works
OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding
Pittenger, C., Adams, T. G., Gallezot, J., Crowley, M. J., Nabulsi, N., Ropchan, J., Gao, H., Kichuk, S. A., Simpson, R., Billingslea, E., et al. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.021 · Cited by 54 · see citing works
Self-citation
Obsessive-Compulsive and Perseverative Behaviors in Huntington’s Disease
Oosterloo, M., Craufurd, D., Nijsten, J. M. H., & van Duijn, E. (2019) · Journal of Huntington s Disease · doi:10.3233/jhd-180335 · Cited by 46 · see citing works
General Overview of Organic Cation Transporters in Brain.
Koepsell, H. (2021) · Handbook of Experimental Pharmacology · doi:10.1007/164_2021_449 · Cited by 32 · see citing works
Neural circuits in goal-directed and habitual behavior: Implications for circuit dysfunction in obsessive-compulsive disorder
Simmler, L. D., & Ozawa, T. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104464 · Cited by 40 · see citing works
Obsessive-Compulsive Disorder (OCD): A Comprehensive Review of Diagnosis, Comorbidities, and Treatment Approaches
Singh, A., Anjankar, V. P., & Sapkale, B. (2023) · Cureus · doi:10.7759/cureus.48960 · Cited by 40 · see citing works
The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap
Szechtman, H., Harvey, B. H., Woody, E. Z., & Hoffman, K. L. (2019) · Pharmacological Reviews · doi:10.1124/pr.119.017772 · Cited by 40 · see citing works
Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder
Sahraian, A., Jahromi, L. R., Ghanizadeh, A. J., & Mowla, A. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000651 · Cited by 39 · see citing works
Glutamate Modulators in the Treatment of Obsessive-Compulsive Disorder
Pittenger, C. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150602-06 · Cited by 37 · see citing works
Self-citation
Perinatal reduction of functional serotonin transporters results in developmental delay
Kroeze, Y., Dirven, B. C. J., Janssen, S., Kröhnke, M., Barte, R. M., Middelman, A., van Bokhoven, H., Zhou, H., & Homberg, J. R. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.012 · Cited by 35 · see citing works
Genetic and epigenetic architecture of Obsessive-Compulsive Disorder: In search of possible diagnostic and prognostic biomarkers
Bellia, F., Vismara, M. E. M., Annunzi, E., Cifani, C., Benatti, B., Dell’Osso, B. M., & D’Addario, C. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.10.040 · Cited by 32 · see citing works
Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
Kelmendi, B., Kichuk, S. A., DePalmer, G., Maloney, G. K., Ching, T. H. W., Belser, A., & Pittenger, C. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12135 · Cited by 34 · see citing works
Self-citation
Long-term consequences of chronic fluoxetine exposure on the expression of myelination-related genes in the rat hippocampus
Kroeze, Y., Peeters, D., Boulle, F., van den Hove, D. V. D., van Bokhoven, H., Zhou, H., & Homberg, J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.145 · Cited by 36 · see citing works
Challenges and Promises of Pediatric Psychopharmacology
Giles, L. L., & Martini, D. R. (2016) · Academic Pediatrics · doi:10.1016/j.acap.2016.03.011 · Cited by 31 · see citing works
Ketamine increases activity of a fronto-striatal projection that regulates compulsive behavior in SAPAP3 knockout mice
Davis, G. L., Minerva, A. R., Lario, A., Simmler, L. D., Rodríguez, C. I., & Gunaydin, L. A. (2021) · Nature Communications · doi:10.1038/s41467-021-26247-2 · Cited by 31 · see citing works
Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications
Vlček, P., Polák, J., Brunovský, M., & Horáček, J. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-118665 · Cited by 30 · see citing works
Closed-Loop Stimulation in Emotional Circuits for Neuro-Psychiatric Disorders
Widge, A. S., & Moritz, C. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802452-2.00017-2 · Cited by 29 · see citing works
Closed-Loop Deep Brain Stimulation for Psychiatric Disorders
Widge, A. S. (2023) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000367 · Cited by 32 · see citing works
Insomnia and related mental health conditions: Essential neurobiological underpinnings towards reduced polypharmacy utilization rates
Fornaro, M., Caiazza, C., Simone, G. D., Rossano, F., & de Bartolomeis, A. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.11.033 · Cited by 28 · see citing works
Neurobiology of maternal mental illness
Maguire, J., McCormack, C., Mitchell, A., & Monk, C. E. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64239-4.00005-9 · Cited by 27 · see citing works
The Effects of Transcranial Direct Current Stimulation in Obsessive–Compulsive Disorder Symptoms: A Meta-Analysis and Integrated Electric Fields Modeling Analysis
Pinto, B. S., Cavendish, B. A., da Silva, P. H. R., Suen, P. J. C., Marinho, K. A. P., Valiengo, L. D. C. L., Vanderhasselt, M., Brunoni, A. R., & Razza, L. B. (2022) · Biomedicines · doi:10.3390/biomedicines11010080 · Cited by 27 · see citing works
How to choose an antidepressant medication
Bayes, A. J., & Parker, G. B. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13001 · Cited by 27 · see citing works
Long-term consequences of chronic fluoxetine exposure on the expression of myelination-related genes in the rat hippocampus
Kroeze, Y., Peeters, D., Boulle, F., van den Hove, D. V. D., van Bokhoven, H., Zhou, H., & Homberg, J. (2015) · Translational Psychiatry · doi:10.1038/tp.2016.60 · Cited by 11 · see citing works
Impact of dissociation on treatment of depressive and anxiety spectrum disorders with and without personality disorders
Praško, J. P., Grambal, A., Kasalová, P., Kamarádová, D., Ocisková, M., Holubová, M., Vrbová, K., Sigmundova, Z., Látalová, K., Šlepecký, M., et al. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s118058 · Cited by 26 · see citing works
A double-blind, placebo-controlled study of inositol in trichotillomania
Leppink, E. W., Redden, S., & Grant, J. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000156 · Cited by 23 · see citing works
The Precision in Psychiatry (PIP) study: Testing an internet-based methodology for accelerating research in treatment prediction and personalisation
Lee, C. T., Palacios, J. E., Richards, D., Hanlon, A. K., Lynch, K., Harty, S., Claus, N., Swords, L., O’Keane, V., Stephan, K. E., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-022-04462-5 · Cited by 23 · see citing works
Dysfunctional beliefs in patients with obsessive-compulsive disorder and depression as assessed with the Beliefs Questionnaire (BQ)
Miegel, F. S., Jelinek, L., & Moritz, S. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.12.070 · Cited by 24 · see citing works
Pregabalin augmentation for resistant obsessive–compulsive disorder: a double-blind placebo-controlled clinical trial
Mowla, A., & Ghaedsharaf, M. (2019) · CNS Spectrums · doi:10.1017/s1092852919001500 · Cited by 25 · see citing works
Obsessive–Compulsive Disorder in Children and Adolescents
Stiede, J. T., Spencer, S. D., Onyeka, O. “., Mangen, K. H., Church, M. J., Goodman, W. K., & Storch, E. A. (2023) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-080822-043910 · Cited by 27 · see citing works
Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder
Pittenger, C., Brennan, B. P., Koran, L. M., Mathews, C. A., Nestadt, G., Pato, M. T., Phillips, K. A., Rodríguez, C. I., Simpson, H. B., Skapinakis, P., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113853 · Cited by 22 · see citing works
Self-citation
Tolerability and adequate therapeutic dosage of oral clomipramine for the treatment of premature ejaculation: A randomized, double-blind, placebo-controlled, fixed-dose, parallel-grouped clinical study
Kim, S. W., Choi, J. B., Kim, S. J., Kim, K. S., Kim, C. M., Lee, D. H., & Choi, W.-S. (2017) · International Journal of Impotence Research · doi:10.1038/s41443-017-0011-5 · Cited by 22 · see citing works
Acute Effects of Cannabis on Symptoms of Obsessive-Compulsive Disorder
Mauzay, D., LaFrance, E. M., & Cuttler, C. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.124 · Cited by 21 · see citing works
Deep brain stimulation for psychiatric disorders and behavioral/cognitive-related indications: Review of the literature and implications for treatment
Mahoney, J. J., Koch-Gallup, N., Scarisbrick, D. M., Berry, J. H., & Rezai, A. R. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120253 · Cited by 21 · see citing works
Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in manic phase of bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial
Sahraian, A., Ehsaei, Z., & Mowla, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.014 · Cited by 21 · see citing works
N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial
Sarris, J., Byrne, G., Castle, D., Bousman, C., Oliver, G., Cribb, L., Blair-West, S., Brakoulias, V., Camfield, D., Ee, C., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110550 · Cited by 19 · see citing works
Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial.
Samadi, R., Soluti, S., Daneshmand, R., Assari, S., & Manteghi, A. A. (2017) · PubMed Central · Cited by 19 · see citing works
Pathway-specific alterations in striatal excitability and cholinergic modulation in a SAPAP3 mouse model of compulsive motor behavior
Malgady, J. M., Baez, A., Hobel, Z. B., Jimenez, K., Goldfried, J., Prager, E. M., Wilking, J. A., Zhang, Q., Feng, G., & Plotkin, J. L. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113384 · Cited by 18 · see citing works
Functional Evaluations of Genes Disrupted in Patients with Tourette’s Disorder
Sun, N., Tischfield, J. A., King, R. A., & Heiman, G. A. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00011 · Cited by 17 · see citing works
The Effect of Orexin Receptor Antagonism on Quinpirole-Induced Compulsive-Like Checking Behavior in Rats
Abounoori, M., Maddah, M. M., Akbari, E., Houshmand, G., & Ardeshiri, M. R. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00196-y · Cited by 16 · see citing works
Variation in Obsessive-Compulsive Disorder Symptoms and Treatments: A Side Effect of COVID-19
Liu, W., Zhang, H., & He, Y. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147420 · Cited by 16 · see citing works
The prefrontal cortex and neurosurgical treatment for intractable OCD
Rasmussen, S. A., & Goodman, W. K. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01149-5 · Cited by 15 · see citing works
Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder
Mowla, A., Boostani, S., & Dastgheib, S. A. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000592 · Cited by 16 · see citing works
Effects of the 5HT2C antagonist SB242084 on the pramipexole-induced potentiation of water contrafreeloading, a putative animal model of compulsive behavior
Schepisi, C., Carolis, L. D., & Nencini, P. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2938-z · Cited by 15 · see citing works
Obsessive compulsive disorder (OCD): Current treatments and a framework for neurotherapeutic research
Woody, E. Z., Hoffman, K. L., & Szechtman, H. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.04.003 · Cited by 16 · see citing works
The serotonergic system in obsessive-compulsive disorder
Derksen, M., Feenstra, M. G. P., Willuhn, I., & Denys, D. A. J. P. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00044-x · Cited by 14 · see citing works
CREB: A Promising Therapeutic Target for Treating Psychiatric Disorders
Guan, W., Meixin, N., Gu, H., & Yang, Y. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240206111838 · Cited by 15 · see citing works
The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report
Marcatili, M., Pellicioli, C., Maggioni, L., Motta, F. L., Chiara, R., Lorenzo, G., Michaela, K., Sibilla, M., Nava, R., Colmegna, F., et al. (2021) · Annals of General Psychiatry · doi:10.1186/s12991-021-00365-z · Cited by 14 · see citing works
Directionality of change in obsessive compulsive disorder and depression over six years of prospective follow-up
Belli, G. M., Law, C., Mancebo, M. C., Eisen, J., Rasmussen, S. A., & Boisseau, C. L. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.11.034 · Cited by 14 · see citing works
Structural and functional brain imaging after treatment with selective-serotonin reuptake-inhibitors in obsessive-compulsive disorder: A mini review
Bracco, L., Dusi, N., Moltrasio, C., Brambilla, P., & Delvecchio, G. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.034 · Cited by 14 · see citing works
Paradigm shift required for translational research on the brain
Yoon, J. H., Lee, D., Lee, C., Cho, E., Lee, S., Cazenave‐Gassiot, A., Kim, K., Chae, S., Dennis, E. A., & Suh, P. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01218-x · Cited by 14 · see citing works
Psilocybin reduces grooming in the SAPAP3 knockout mouse model of compulsive behaviour
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110202 · Cited by 16 · see citing works
Suicidal Ideation and Obsessive-Compulsive Disorder: Links and Knowledge
Benster, L. L., Weissman, C. R., & Daskalakis, Z. J. (2022) · Psychology Research and Behavior Management · doi:10.2147/prbm.s368585 · Cited by 15 · see citing works
Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder
Harmelech, T., Roth, Y., & Tendler, A. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.10.003 · Cited by 14 · see citing works
Escitalopram reversibility of the impacts following chronic stress on central 5-HT profiles – Implications to depression and anxiety
Lin, C.-C., Yang, C.-P., Cheng, P., Hsiao, M., & Liu, Y. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114613 · Cited by 14 · see citing works
Deep brain stimulation, lesioning, focused ultrasound: update on utility
Reddy, A., Hosseini, M. R., Patel, A., Sharaf, R., Reddy, V. K., Tabarestani, A., & Lucke-Wold, B. P. (2023) · AIMS neuroscience · doi:10.3934/neuroscience.2023007 · Cited by 14 · see citing works
The use of antipsychotics in obsessive compulsive disorder
Conti, D., Girone, N., Boscacci, M., Casati, L., Cassina, N., Cerolini, L., Giacovelli, L., Viganò, C. A., Conde, M. M., Cremaschi, L., et al. (2024) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2893 · Cited by 13 · see citing works
A potential role for psilocybin in the treatment of obsessive-compulsive disorder
Jacobs, E. (2020) · Journal of Psychedelic Studies · doi:10.1556/2054.2020.00128 · Cited by 16 · see citing works
Prevalence of Obsessive-Compulsive Disorder in Patients With Schizophrenia and Outcome on Positive and Negative Symptoms, Cognition, and Quality of Life
Wehbé, J., Haddad, C., Obeïd, S., Hallit, S. R., & Haddad, G. (2019) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000956 · Cited by 13 · see citing works
Efficacy of cognitive behavioural therapy with medication for patients with obsessive-compulsive disorder: A multicentre randomised controlled trial in China
Meng, F., Han, H., Luo, J., Liu, J., Liu, Z., Tang, Y., Hou, X., Wei, J., Shi, L., Tang, M., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.090 · Cited by 12 · see citing works
Deep transcranial magnetic stimulation for obsessive compulsive disorder
McCathern, A. G., Mathai, D. S., Cho, R. Y., Goodman, W. K., & Storch, E. A. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1798232 · Cited by 12 · see citing works
Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorder
Gattuso, J. J., Kong, G., Bezcioglu, B., Lu, D., Ekwudo, M. N., Wilson, C., Gubert, C., Hannan, A. J., & Renoir, T. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110648 · Cited by 11 · see citing works
Transcranial direct current stimulation for Obsessive-Compulsive Disorder: patient selection and perspectives
da Silva, R. D. M. F., Brunoni, A. R., Miguel, E. C., & Shavitt, R. G. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s184839 · Cited by 11 · see citing works
Direct changes of neurometabolic concentrations in the pregenual anterior cingulate cortex among obsessive-compulsive patients after repetitive transcranial magnetic stimulation treatment
Luo, G., Wang, S., Yao, S., Quan, D., Guo, G., Gao, J., & Zheng, H. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.052 · Cited by 11 · see citing works
Naturalistic operant responses in deer mice (Peromyscus maniculatus bairdii) and its response to outcome manipulation and serotonergic intervention
de Brouwer, G., Harvey, B. H., & Wolmarans, D. W. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000536 · Cited by 11 · see citing works
Treatment of refractory obsessive–compulsive disorder with nutraceuticals (TRON): a 20-week, open label pilot study
Sarris, J. J., Byrne, G. J., Oliver, G., Cribb, L., Blair‐West, S., Castle, D. J., Dean, O. M., Camfield, D., Brakoulias, V., Bousman, C., et al. (2021) · CNS Spectrums · doi:10.1017/s1092852921000638 · Cited by 12 · see citing works
Generalized Anxiety Disorder (GAD) in a teaching laboratory beagle: Presentation, relative contributions, and treatment
Squair, C. (2023) · Journal of Veterinary Behavior · doi:10.1016/j.jveb.2023.05.008 · Cited by 10 · see citing works
The role of the dorsal anterior cingulate cortex in obsessive-compulsive disorder
van de Veerdonk, M. M. G. H., van der Vlis, T. A. M. B., Ackermans, L. P. C. M., Schruers, K. R. J., Temel, Y., & Leentjens, A. F. G. (2023) · Deep Brain Stimulation · doi:10.1016/j.jdbs.2023.07.001 · Cited by 12 · see citing works
Efficacy and tolerability of vortioxetine monotherapy in SSRI-resistant OCD: a retrospective multicenter study
Martiadis, V., Pessina, E., Cattaneo, C. I., Martini, A., Raffone, F., Prodi, T., Olivola, M., Berardis, D. D., Benatti, B., & Dell’Osso, B. M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1617345 · Cited by 11 · see citing works
Association of granulocyte macrophage colony-stimulating factor and interleukin-17 levels with obsessive–compulsive disorder: a case–control study findings
Sarker, R., Qusar, M. S., Islam, S. M. A., Bhuiyan, M. A., & Islam, M. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-46401-8 · Cited by 10 · see citing works
Metacognitive beliefs predict early response to pharmacological treatment in patients with obsessive–compulsive disorder
Park, C. I., Kim, H. W., Jeon, S., Hwang, E. H., Kang, J. I., & Kim, S. J. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05630-9 · Cited by 11 · see citing works
Relationship of bipolar disorder with psychiatric comorbidity in the postpartum period—a scoping review
Sharma, V. (2017) · Archives of Women s Mental Health · doi:10.1007/s00737-017-0782-1 · Cited by 11 · see citing works
Enhancing the efficacy of 5-HT uptake inhibitors in the treatment of attention deficit hyperactivity disorder
Riley, T. B., & Overton, P. G. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109407 · Cited by 9 · see citing works
Dopaminergic and serotonergic modulation of social reward appraisal in zebrafish (Danio rerio) under circumstances of motivational conflict: Towards a screening test for anti-compulsive drug action
van Staden, C., de Brouwer, G., Botha, T. L., Finger‐Baier, K., Brand, S. J., & Wolmarans, D. W. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112393 · Cited by 9 · see citing works
Systematic review of studies using platelet serotonin content to assess bioeffect of serotonin reuptake inhibitors at the serotonin transporter
Anderson, G. M., & Bruno-Pacella, I. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06276-5 · Cited by 9 · see citing works
Using caffeine on the patients as therapeutic option against treatment-resistant obsessive-compulsive disorder
Soufi, E., Shams, J., Zahiroddin, A., & Shekarriz‐Foumani, R. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_93_19 · Cited by 9 · see citing works
A systematic review and narrative synthesis of the use and effectiveness of extended reality technology in the assessment, treatment and study of obsessive compulsive disorder
Colman, M. D., Millar, J. F. A., Patil, B., Finnegan, D. J., Russell, A., Higson‐Sweeney, N., Aguiar, M. D. S., & Fraser, D. S. (2024) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2024.100893 · Cited by 9 · see citing works
The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials
Eghdami, S., Eissazade, N., Mokarrar, M. H., Boroon, M., Orsolini, L., & Shalbafan, M. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1421150 · Cited by 8 · see citing works
Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study
Giacovelli, L., Piccoli, E., Landi, P., Vismara, M. E. M., Benatti, B., & Dell’Osso, B. M. (2025) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000583 · Cited by 8 · see citing works
Motor cortical inhibitory deficits in patients with obsessive-compulsive disorder–A systematic review and meta-analysis of transcranial magnetic stimulation literature
da Silva, D. R., Maia, A., Cotovio, G., Oliveira, J., Oliveira-Maia, A. J., & Barahona-Corrêa, B. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1050480 · Cited by 8 · see citing works
Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review
Strouphauer, E., Morris, O. J., Soileau, K. J., Wiese, A. D., Quast, T. C., Goodman, W. K., Sheth, S. A., Wojcik, K. D., Guzick, A. G., & Storch, E. A. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01250-1 · Cited by 8 · see citing works
Prediction of pharmacological response in OCD using machine learning techniques and clinical and neuropsychological variables
Tubío-Fungueiriño, M., Cernadas, E., Fernández-Delgado, M., Arrojo, M., Bertolín, S., Real, E., Menchón, J. M., Carracedo, Á., Alonso, P., Fernández‐Prieto, M., et al. (2024) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.sjpmh.2024.11.001 · Cited by 9 · see citing works
Is quetiapine effective for obsessive and compulsive symptoms in patients with bipolar disorder? A randomized, double-blind, placebo-controlled clinical trial
Sahraian, A., Ghahremanpouri, B., & Mowla, A. (2021) · CNS Spectrums · doi:10.1017/s1092852921000572 · Cited by 8 · see citing works
Striatal adenosine A2A receptor involvement in normal and large nest building deer mice: Perspectives on compulsivity and anxiety
Saaiman, D., Brand, L., de Brouwer, G., van Rensburg, H. D. J., Terre’Blanche, G., Legoabe, L. J., Krahe, T. E., & Wolmarans, D. W. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114492 · Cited by 8 · see citing works
Neuropsychological performance and predictors of pharmacological treatment response in obsessive compulsive disorder
Tubío-Fungueiriño, M., Alemany-Navarro, M., Alonso, P., Arrojo, M., Real, E., Bertolín, S., Menchón, J. M., Carracedo, Á., Fernández‐Prieto, M., & Segalàs, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.063 · Cited by 7 · see citing works
The Role of Epigenetics in OCD: A Multi-order Adaptive Network Model for DNA-Methylation Pathways and the Development of OCD
Huisman, L., Ong, C., van de Werken, M., & Jan Treur, A. (2024) · IFIP advances in information and communication technology · doi:10.1007/978-3-031-63211-2_18 · Cited by 7 · see citing works
The Serotonergic System in Obsessive-Compulsive Disorder
van Dijk, A., Klompmakers, A. A., & Denys, D. A. J. P. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70100-4 · Cited by 7 · see citing works
Evidence-Based Treatments in Treatment-Naïve and Treatment-Resistant Pediatric Obsessive-Compulsive Disorder
Skarphéðinsson, G., & Ivarsson, T. (2015) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-015-0047-0 · Cited by 7 · see citing works
Adequacy of treatment in outpatients with obsessive-compulsive disorder
Cohen, S. E., Storosum, B. W. C., Vulink, N. C. C., de Koning, P. P., Namavar, Y., Zantvoord, J. B., & Denys, D. A. J. P. (2024) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2024.152546 · Cited by 6 · see citing works
The Motivational Determinants of Human Action, Their Neural Bases and Functional Impact in Adolescents With Obsessive-Compulsive Disorder
Perkes, I. E., Morris, R. W., Griffiths, K. R., Quail, S. L., Waters, F. A., O’Brien, M., Hazell, P., & Balleine, B. W. (2022) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2022.11.004 · Cited by 6 · see citing works

The Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.11.005 · Cited by 26 · see citing works
Self-citation
Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults
Fineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150 · see citing works
A Review of Pharmacologic Treatments for Obsessive-Compulsive Disorder
Kaplan, A., & Hollander, E. (2003) · Psychiatric Services · doi:10.1176/appi.ps.54.8.1111 · Cited by 105 · see citing works
Pharmacological treatment for obsessive–compulsive disorder
Fineberg, N. A., & Craig, K. J. (2007) · Psychiatry · doi:10.1016/j.mppsy.2007.04.001 · Cited by 26 · see citing works
The Psychopharmacological Treatment of Obsessive-Compulsive Disorder
Insel, T. R., & Murphy, D. L. (1981) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198109000-00006 · Cited by 78 · see citing works

Authors: Pittenger, C., & Bloch, M. H.
Affiliations: Yale University (US)
Corresponding author: Pittenger, Christopher
ORCID: Pittenger, Christopher
Bloch, Michael H.
Venue: Psychiatric Clinics of North America
Publisher: Elsevier BV
Published: 2014-09
Volume: 37
Issue: 3
Pages: 375-391
ISSN: 0193-953X (ISSN-L)
DOI: 10.1016/j.psc.2014.05.006
PMC: PMC4143776
OpenAlex: W1997452831
Cited by: 222
References: 79
Citations by year: 2026: 24 · 2025: 25 · 2024: 31 · 2023: 32 · 2022: 21 · 2021: 16 · 2020: 17 · 2019: 16 · 2018: 8 · 2017: 7 · 2016: 12 · 2015: 10 · 2014: 1 · 2012: 1
FWCI: 1.52
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Psychiatric Clinics of North America (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR000142)
National Institute of Mental Health (R01MH095790, R34MH083115, K23MH091240, R25MH077823)
National Center for Advancing Translational Sciences
Topics: Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
Keywords: obsessive-compulsive disorder, pharmacotherapy, selective serotonin reuptake inhibitors, clomipramine, tricyclic antidepressants, treatment-resistant OCD, second-line therapy
MeSH terms: Combined Modality Therapy, Drug Therapy, Combination, Nonprescription Drugs, Humans, Obsessive-Compulsive Disorder, Psychotherapy, Psychotropic Drugs, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacological Treatment of Obsessive-Compulsive Disorder

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks